Vanta Bioscience Quarterly Results
Vanta Bioscience quarterly results. In Mar 2023, Vanta Bioscience (VANTABIO) reported revenue ₹1 Cr and net profit ₹-1 Cr — revenue -80.0% YoY. Check VANTABIO market value to track the company's total market size over time.
VANTABIO Quarterly Results — Revenue, Profit & EPS Highlights
Vanta Bioscience latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit VANTABIO stock price BSE.
- Revenue of ₹1 Cr in Mar 2023 (-80.0% vs Mar 2022, -80.0% vs Mar 2022)
- Net Profit of ₹-1 Cr in Mar 2023
- EBITDA of ₹-1 Cr in Mar 2023 (-150.0% vs Mar 2022)
- Operating Margin of -206.0% in Mar 2023 (-252.0pp vs Mar 2022)
Vanta Bioscience Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VANTABIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2023 | Mar 2022 | Dec 2022 | Dec 2021 | QoQ | YoY |
|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1 | 5 | 3 | 0 | -80.0% | -80.0% |
| Net Profit (₹ Cr) | -1 | 0 | -3 | 0 | - | - |
| EBITDA (₹ Cr) | -1 | 2 | -1 | 0 | - | - |
| EPS (₹) | 0.00 | 0.11 | -4.06 | 0.00 | - | - |
| Operating Margin (%) | -206.0% | 46.0% | -20.0% | 0.0% | - | - |
VANTABIO Share Price Trend — 1-Year Movement Across Quarterly Results
Vanta Bioscience 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review VANTABIO earnings valuation to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VANTABIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vanta Bioscience latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹421,995.00 Cr | 1758.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 155.6 |
|
Divis Laboratories
Mar 2026 |
₹241,231.30 Cr | 9162.0 | 2,986 | 751 | -5.0% | - | 25.2% | 323.6 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4615.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 401.0 |
|
Laurus Labs
Mar 2026 |
₹111,790.60 Cr | 2002.5 | 1,823 | 282 | -10.5% | - | 15.5% | 387.3 |
|
Zydus Life Science
Mar 2026 |
₹111,111.95 Cr | 1135.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 89.7 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores